Schizofrenia: badanie fazy II leku vafidemstat

Kryteria wyłączenia kto nie może wziąć udziału (26)

1. Failure to perform screening or baseline procedures.
2. Is treatment resistant. Treatment resistance is defined as inadequate response in the level of psychotic symptoms during more than two (2) documented treatment courses with adequate doses of antipsychotic medications prescribed for adequate periods of time (i.e., at least lasting for 6 weeks) within 2 years prior to the Screening Visit.
3. Diagnosis with any DSM-5 Schizophrenia Spectrum and Other Psychotic Disorders other than schizophrenia.
4. Undergoing gender reassignment and, particularly, gender affirming hormone treatments.
5. DSM-5 diagnosis of neurodevelopmental disorders including, but not limited to, intellectual disability, autism spectrum disorder as well as bipolar disorder and related disorders or major depressive disorder (MDD) with psychosis.
6. Current DSM-5 diagnosis of anorexia nervosa, bulimia nervosa, binge-eating disorder, oppositional defiant disorder, intermittent explosive disorder, conduct disorder, antisocial personality disorder, paranoid personality disorder, borderline personality disorder or obsessive-compulsive disorder
7. Current DSM-5 diagnosis of panic disorder or agoraphobia. Participants with post-traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), MDD without psychosis, attention deficit hyperactivity disorder (ADHD) are eligible if symptoms have been stable for at least 90 days prior to the Screening visit, these disorders are not the primary focus of treatment, changes in any treatment for these disorders would not likely be required for the duration of the study, and in the investigator´s opinion these disorders will not interfere with the assessment and/or accuracy of the study endpoints.
8. Current diagnosis or a history of substance use disorder according to DSM-5™ criteria within 6 months prior to the Screening Visit. a. Nicotine, caffeine, alcohol and/or cannabis use is not prohibited unless it qualifies as a substance use disorder per DMS-5™.
9. Use of illicit drugs for at least one week before Screening and participants unwilling to abstain from use of these substances during the study. Regarding cannabis, patient self-report of abstinence within 24 hours will be used for inclusion decision-making versus the urine drug test results.
10. Use of alcohol or cannabinoids within 24 hours of a study visit.
11. Suicide attempt or significant risk of suicide within 6-months prior to the Screening visit or the period between Screening and Baseline visit, defined as a “yes” to suicidal ideation questions 4 or 5, or answering “yes” to suicidal behavior on the Columbia-Suicide Severity Rating Scale.
12. The participant is in formal structured nonpharmacological psychosocial therapeutic treatment program (e.g. formal cognitive, behavioral therapy, systematic psychotherapy or vocational rehabilitation, including but not limited to cognitive remediation, cognitive-behavioral therapy, intensive symptom/vocational rehabilitation) for a duration of less that (<3) months before Screening. Any ongoing structured nonpharmacological psychosocial therapeutic treatment initiated more than 3 months prior to Screening should be continued with the same frequency and intensity during the entire study.
13. A previous or current diagnosis of neuroleptic malignant syndrome.
14. Treated with and is resistant to clozapine according to the investigator’s judgement.
15. Hospitalization or medication change for any reason 3 months (see inclusion criteria #6) prior to the Screening visit or during the Screening period that makes the participant medically or mentally unsuitable for trial participation.
16. Clinically significant, advanced, or unstable disease that is likely to result in rapid deterioration of the participant’s condition or affect their safety during the study, including but not limited to: a. Seizure disorders, excluding febrile seizures of childhood b. Respiratory insufficiency, the status must be determined as usual clinical practice c. Hepatic impairment (serum values of total bilirubin value, alanine aminotransferase [ALT], aspartate aminotransferase [AST] and/or gamma-glutamyl transferase [GGT] 1.5 times the upper limit of normal [ULN]). Any elevations greater than 1.5 times the ULN will be reviewed by the Medical Monitors on a case-by-case basis, and these participants will only be allowed with Sponsor approval. d. Renal insufficiency (serum creatinine >2mg/dl) e. Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before Screening visit) f. Hypertension treatment with more than 2 drugs g. Atrioventricular block (type II/Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF-interval (males >450 msec and females >470 msec) h. Uncontrolled diabetes (Hb1Ac >7.5) i. Hematological disorders j. Platelets <130,000/mm3 and/or neutrophils <1,800/mm3 k. Malignant tumors within the last 5 years other than basal cell or Stage 1 squamous cell carcinoma of the skin l. Moderate-to-severe traumatic brain injury
17. Positive results for tuberculosis (the status must be determined as usual clinical practice, that is, by medical history, signs, and symptoms), Human Immunodeficiency Virus (HIV), Hepatitis C or Hepatitis B (Hepatitis B surface antigen [HBsAg]) serology obtained at the Screening Visit
18. Uncontrolled hypo- or hyperthyroidism at Screening Visit, based on laboratory parameters.
19. Clinically significant infection within the previous 30-days (e.g., persistent, or acute infection such as a urinary tract infection or upper respiratory infection).
20. Chronic drug intake of: a) Anticoagulants (only 81 mg/day acetylsalicylic acid is permitted) b) Corticosteroids or immunosuppressant (only inhaled or topical suspension are allowed) c) Myelosuppressive treatments such as chemotherapy and radiation d) Medications known to be UGT inhibitors or inducers should be used with caution (*) - (*) UGT Inhibitors (e.g.: adenine, propofol, flunitrazepam, ertugliflozin, ketoconazole, valproic acid, flurbiprofen, silibinin, sodium aurothiomalate, gemfibrozil, deferasirox, probenecid, amitriptyline, indomethacin, ubrogepant) - UGT inducers (e.g.: carbamazepine, phenytoin, phenobarbital, rifampicin, testosterone propionate, lamotrigine, primidone, ethinylestradiol, desogestrel, orthosiphon stamineus) These lists are not intended to be exhaustive. Drug-Drug Interactions (DDI) interactions should be reviewed on the label. e) Hypnotics as Z-drugs – i.e.: zaleplon, zolpidem, zopiclone – are allowed in occasional short-term prescription. Participants should not have this medication within 24 hours before any study visit. f) The concomitant use of short and medium half-life oral benzodiazepines in stable dose for at least 3 months before the Screening visit is allowed for the treatment of psychiatric comorbidities (as per inclusion/exclusion criteria) when these medications are prescribed as per their labelled indications. The dose should remain stable throughout the study. g) The concomitant use of MAO inhibitors and antidepressants in stable dose for at least 3 months before the Screening visit is allowed for the treatment of psychiatric comorbidities (as per inclusion/exclusion criteria) when these medications are prescribed as per their labelled indications XX. XXXXXX h) The concomitant use of typical antipsychotics is forbidden. The concomitant use of atypical antipsychotics (except clozapine, which is forbidden), in stable dose for at least 3 months before Screening visit is allowed for the treatment of psychiatric comorbidities (as per inclusion/exclusion criteria) when these medications are prescribed as per their labelled indications. The dose should remain stable throughout the study. i) The concomitant use of mood stabilizers in stable dose for at least 3 months before Screening visit is allowed for the treatment of psychiatric comorbidities (as per inclusion/exclusion criteria) when these medications are prescribed as per their labelled indications. j) The concomitant use of nootropics; for instance, racetams, amphetamines, methylphenidate, levodopa, atomoxetine, preparations containing Gingko biloba, is forbidden throughout the study and two weeks before the Screening visit. k) The concomitant use of centrally active anti-hypertensive drugs, such as clonidine, a-methyldopa and guanfacine hydrochloride, as well as guanethidine, is forbidden throughout the study and two weeks before the Screening visit. l) The concomitant use of medications which may have an impact on blood cells count changes should be used with caution (e.g.: heparin, quinine, quinidine, penicillin, sulphonamides, NSAIDs, anticonvulsants, antirheumatics, oral antidiabetics, gold salts, diuretics rifampicin, ranitidine). This list is not intended to be exhaustive. Drug-Drug Interactions (DDI) interactions should be reviewed in the label of the concomitant medications. m) The concomitant use of platelet aggregation inhibitors should be used with caution (e.g.: COX-2 inhibitors, ADP receptor inhibitors, thromboxane inhibitors). This list is not intended to be exhaustive. Drug-Drug Interactions (DDI) interactions should be reviewed in the label of the concomitant medications.
21. Esketamine and psychedelic treatments (e.g. psilocybin or ketamine) in the past 90 days before the Screening visit.
22. Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in the past 3 months before the screening visit, and during the trial.
23. Any regular intake of medications acting directly on the central nervous system that investigator believes may impact cognition or function.
24. Member or immediate family of the study personnel or subordinate to any of the study personnel.
25. Enrollment in another investigational study or intake of investigational drug within the previous 3 months.
26. Any condition that in the opinion of the investigator makes the participant unsuitable for inclusion in the study.